Skip to content
DataLookout
Menu

NCT07937605

KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast Cancer

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Progression-free survival (PFS)
Timeframe: Baseline to study completion (approximately 48 months)
Adverse events (AEs)
Timeframe: Baseline to study completion (approximately 48 months)

Secondary (4)

Objective Response Rate (ORR)
Disease Control Rate (DCR)
Duration of Response (DOR)
Time to Response (TTR)

Arms and interventions

Part1Experimental

This is a single-arm dose-escalation phase. Participants will receive one of three KC1086 doses (1 mg, 2 mg, or 4 mg once daily) in combination with a fixed dose of fulvestrant.

Part2Experimental

This is a randomized controlled phase. Participants will be randomized in a 2:2:1 ratio to receive low-dose KC1086 plus fulvestrant, high-dose KC1086 plus fulvestrant, or everolimus plus fulvestrant or exemestane.

Drugs: KC1086, Fulvestrant, Everolimus (10 mg QD), Exemestane